Solid Biosciences (SLDB)
(Delayed Data from NSDQ)
$7.85 USD
-0.79 (-9.14%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $7.85 0.00 (0.00%) 7:24 PM ET
4-Sell of 5 4
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SLDB 7.85 -0.79(-9.14%)
Will SLDB be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SLDB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SLDB
Here's Why Sarepta (SRPT) Stock Price Surged 57% YTD
FDA Expands Sarepta's (SRPT) DMD Gene Therapy Label
SLDB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Solid Biosciences (SLDB) Falls Despite FDA Rare Tag for DMD Drug
Beat the Market Like Zacks: Walmart, Novo Nordisk, Procter & Gamble in Focus
REGENXBIO (RGNX) Soars 15% on Interim Data From DMD Study
Other News for SLDB
REGENXBIO releases new data on DMD drug ahead of earnings
PepGen stock tumbles 25% following release of DMD drug data
Analysts Offer Insights on Healthcare Companies: Envista Holdings (NVST), Solid Biosciences (SLDB) and Lexeo Therapeutics, Inc. (LXEO)
Solid Biosciences’ SGT-003: A Promising Leap in DMD Therapy with Cardiac Safety Superiority
Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)